https://go.evvnt.com/223758-0?pid=5248 The Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
Lectures & Conferences
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapy, the inaugural Hemophilia Drug Development Summit plays host to the leading pharma and biotech players working to develop longer acting and more efficacious therapies to overcome significant unmet medical need and prevent resistance to factor replacement therapies.
Fueled by current investment in the space and novel therapeutic strategies to improve current standard of care, the development of hemophilia therapeutics has been reinvigorated. Touted as an area of large unmet medical need but a well understood and defined disease profile, investment in this space is set to grow.
Attend the inaugural Hemophilia Drug Development Summit to identify novel drug development strategies’ from therapeutic antibodies through to gene therapies and bring life-changing treatments to patients in need.
Attending this industry driven forum will enable you to:
- Harness new understanding of the biological and long term impacts of these novel therapies
- Optimize your clinical trial design to save time and costs
- Define suitable endpoints so that the benefits of your therapy are clear and apparent
Conference + 2 Workshops USD 2398.0
Conference + 1 Workshop USD 1949.0
Conference Only USD 1499.0
Speakers: Daniel Leonard, Director of Global Patient Advocacy, UniQure, Craig Benson, Clinical Research Director, Sanofi Genzyme, Alison Schecter, Global Program Head, Rare Disease, Sanofi Genzyme, Leonard Valentino, Vice President, Hematology, Spark Therapeutics, Sabah Sallah, Vice President, Gene Therapy, Liver Directed Diseases, UniQure, Lotta Jansson, Chief Research Officer, Apitope, Chris Haskell, Vice President, Head of the West Coast Innovation Center, Bayer, Robert Peters, Senior Vice President Research, Bioverativ, Howard Levy, Chief Medical Officer, Catalyst Biosciences, Henry Mead, Global Medical Director Hematology, CSL Behring, Michelle Rice, Senior Vice President External Affairs, National Hemophilia Foundation, Mark Skinner, President & CEO, Institute for Policy Advancement, Michael Ero, President and Founder, Machaon Diagnostics, Robert Kotin, Professor, UMass Medical School, Christopher Walsh, Director, Hemophilia Program, Mount Sinai School of Medicine, Elizabeth Stoltz, Advocacy and Policy Consultant, National Hemophilia Foundation, Jesper Haaning, Project Vice President, Global Development, Novo Nordisk, Irina Matytsina, International Medical Director, Global Development, Novo Nordisk, Valder Arruda, Chair, Gene Therapy and Vaccines Program, University of Pennsylvania